UGN-102 Yields Complete Responses in Non-Muscle Invasive Bladder Cancer
If approved, UGN-102 may become the first non-surgical option for patients with low-grade intermediate-risk non–muscle invasive bladder cancer, says Sandip Prasad, MD.
Nadofaragene Firadenovec Produces Enduring Clinical Activity in NMIBC
Data from the phase 3 CS-003 study underscore the importance of long-term follow-up findings with novel therapies for high-grade non–muscle-invasive bladder cancer, says Stephen A. Boorjian MD.
Data on Socioeconomic Disparities in Clear Cell RCC Care Are ‘Actionable’
African American and Hispanic patients with clear cell renal cell carcinoma may be less likely to receive treatment with immune checkpoint inhibitors than White patients, says Solomon Woldu, MD.
Chemo/Nephroureterectomy Increases pCR Likelihood in Urothelial Carcinoma
Patients receiving neoadjuvant chemotherapy plus radical nephroureterectomy for upper tract urothelial carcinoma appear more likely to experience nodal downstaging.
FDA Gives Accelerated Approval to Pirtobrutinib in CLL/SLL
Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib.
Cretostimogene Grenadenorepvec May be ‘Attractive’ Option for NMIBC
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Data Show Barriers to Immunotherapy Access in Clear Cell RCC Population
Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.
FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer
The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.
Cretostimogene Grenadenorepvec Yields Durable Responses in NMIBC
More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.
Digital Pathology and AI May be ‘Valuable Tools’ in Prostate Cancer
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma
Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.
Cadonilimab Combo Improves PFS in Recurrent/Metastatic Cervical Cancer
Investigators note a trend towards improved overall survival with cadonilimab plus chemotherapy with or without bevacizumab among those with cervical cancer in the phase 3 AK104-303 trial.
Data Show Short-Course Radiotherapy Increase in Prostate Cancer
Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.
Genetic Prostate Cancer Studies Are Needed to Push the Needle Forward
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
BI 764532 Earns FDA FTD in Large Cell Lung Neuroendocrine Carcinoma
Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.
Tisotumab Vedotin Survival Data in Cervical Cancer Are “Game-Changing”
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
FDA Warns BCMA-, CD19-Directed Autologous CAR T-Cell Therapy May Lead to T-Cell Malignancies
Six BCMA-directed, CD19-directed autologous CAR T-cell therapies are under investigation for the potential risk of T-cell malignancies.
Nirogacestat Approval Offers Choice to Desmoid Tumor Population
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers
Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.
Epcoritamab Earns FDA BTD in Relapsed/Refractory Follicular Lymphoma
Data from the phase 1/2 EPCORE NHL-1 trial support the FDA breakthrough therapy designation for epcoritamab-bysp in patients with previously treated relapsed/refractory follicular lymphoma.
Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma
Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.
FDA OKs Nirogacestat for Treatment of Desmoid Tumors
Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.
Apixaban Yields No Significant Benefit in Acute Lymphoblastic Leukemia
Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.
Frontline Advanced Endometrial Cancer Therapy Confers High Economic Burden
Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.
FDA Receives BLA for Obe-cel in R/R Acute Lymphoblastic Leukemia
Data from the phase 2 FELIX study support the biologics license application for obecabtagene autoleucel as a treatment for patients with relapsed/refractory acute lymphoblastic leukemia.
More Screening Advocacy Is Needed to Improve Breast Cancer Surgery Outcomes
The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.
Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer
Significant progression-free survival was seen in those with TP53 wild-type advanced/recurrent endometrial cancer who were treated with maintenance selinexor.
Radiation Oncologist Speaks to AI Potential in the Cancer Space
Richard Bakst, MD, speaks to the potential use of artificial intelligence in the radiation oncology space, and how he hopes to see it evolve.
FDA Publishes Final Guidelines for Real-time Review of Oncology Drugs
The FDA finalizes the guidelines of its real-time oncology review to state that submissions must include clinical trial end points that can be “easily interpreted.”
